Pharmacological and animal models utilizing HSP expression (elevated HSP70 and reduced HSP90) have reduced the aggregation and toxicity of alpha-synuclein in Parkinson’s disease (Auluck et al., 2002; Klucken et al., 2004; Danzer et al., 2011; Gao et al., 2015). The gene discussed is HSP90B2P; the disease is Parkinson disease.